Veteran biopharmaceutical executive brings deep capital-raising, M&A, and product launch experience to lead ThyrOxy platform development.

The USPTO grant extends ThyrOxy intellectual property estate to five issued global patents and protects a novel clinical dosing methodology developed by Herald’s scientific co-founders. The new claims protect direct-to-lung T3 administration with serum-guided dose titration in ARDS.

David Ingbar, MD, and Robert Schumacher, PhD, receive a $1 million Transformational Research Award from the Dr. Ralph and Marian Falk Medical Research Trust.

Herald Therapeutics awarded second place in the Life Science/HealthIT division at the 2025 MN Cup competition, out of 144 competitors.

Robert J. Schumacher, PhD, and David H. Ingbar, MD, have received a $106,300 grant from the Minnesota Partnership for Biotechnology and Medical Genomics, through the Translational Product Development Fund.

David Ingbar, MD, and Robert Schumacher, PhD, receive a two-year, $350,000 Catalyst Research Award from the Dr. Ralph and Marion Falk Medical Research Trust.